Market data, consumer behavior, and channel shifts after the FDA opened OTC hearing aid sales
SEER SONUS Research·
Figure · Forecast vs. Reality
Pre-rule optimism saw OTC hitting US$8B and 30–40% of the global market within five years. Two years on, the actual 2024 OTC market is just US$200–300M and ~5% of U.S. shipments—under 4% of the forecast.
Regulatory Background & Timeline
The opening of the U.S. OTC hearing aid market was no overnight event—it was a six-year policy evolution spanning four Congresses and the interests of millions of people with hearing loss. From the National Academies' 2016 report to the FDA Final Rule of 2022, the journey reflects a deep debate over consumer access versus the safety of professional fitting.
2016
NASEM publishes its Hearing Health Care for Adults report
The U.S. National Academies first recommended creating an OTC hearing aid category to give people with hearing loss an affordable, prescription-free option.
2017
OTC Hearing Aid Act signed into law
Championed by Senators Elizabeth Warren and Chuck Grassley and passed with bipartisan support, the act required the FDA to establish an OTC category within three years.
2020
FDA releases its Proposed Rule
Delayed by the COVID-19 pandemic, the FDA did not open public comment until October 2021, ultimately receiving more than 1,000 submissions.
2022.08
FDA Final Rule takes effect
Formally established the OTC hearing aid category (21 CFR Part 800) for adults 18+ with perceived mild-to-moderate hearing loss, with a maximum output of ≤117 dB SPL.
2022.10
OTC hearing aids hit retail shelves
Brands such as Sony, Jabra, and Lexie by Bose entered Best Buy, Walmart, and CVS as the first wave of OTC products.
Key OTC Regulatory Parameters
Eligibility: Adults 18+ with perceived mild-to-moderate hearing loss
Maximum output: ≤117 dB SPL (≤130 dB SPL for devices with gain control)
Sales channels: Retail and online, with no audiologist prescription or fitting required
Labeling: Must clearly state the OTC category, usage instructions, and limitations
Exclusions: Severe/profound hearing loss, under 18, and unilateral hearing loss
Market Penetration: Data vs. Hype
Before OTC deregulation, industry and media forecasts ran high—several research firms projected the OTC market would reach US$5–8B within five years, capturing 30–40% of the global hearing aid market. Two years on, the real data tells a far more modest story.
OTC vs. prescription hearing aids — U.S. unit shipment trend (10,000s)
Prescription hearing aids
OTC hearing aids
US$200–300M
Actual 2024 OTC market size
~5%
OTC share of total U.S. shipments
US$8B
Pre-rule optimistic forecast (2027)
25–40%
Estimated OTC return rate
Why has OTC underperformed?Four structural barriers continue to constrain OTC penetration:
01
Consumer confusion
Faced with dozens of OTC products, people with mild hearing loss struggle to judge their own type and degree of loss. Without audiologist guidance, "which one should I buy?" becomes the primary barrier.
02
No insurance coverage
Medicare still does not cover OTC hearing aids, and most commercial plans exclude them. A US$500–1,000 out-of-pocket cost remains a hurdle for those with mild loss, who often don't believe they "need" a hearing aid.
03
High return rates
Industry estimates put OTC return rates at 25–40%, far above the ~5% for professional fitting—driven by self-fitting discomfort, sound-quality expectation gaps, and the absence of follow-up adjustment.
04
Retail channels lack hearing expertise
Staff at retailers like Best Buy and Walmart lack audiology training and can't offer basic product-selection or fitting guidance, essentially leaving consumers to figure it out themselves.
Placing OTC in a global context:
Market
OTC / self-purchase status
Adoption rate
Notes
United States
OTC formally opened in 2022
~30%
OTC ~5% of shipments and growing
Japan
Thriving sound-amplifier market (de facto OTC)
~14%
600,000 amplifiers sold annually, but mostly low quality
European Union
Still predominantly prescription-based
~35%
France's 100% Santé scheme is lifting adoption
Product Landscape & Pricing Analysis
The OTC product landscape is sharply two-tiered—consumer-electronics majors offer branded products at US$699–999, while unbranded Amazon listings run US$50–200, forming two distinct market segments. The middle is nearly empty, forcing consumers to choose between quality-but-expensive and cheap-but-uncertain.
Product
Price (/pair)
Type
App
Bluetooth
Self-fitting
Water resistance
Rating
Sony CRE-E10
US$999
CIC
✓
✓
✓
IPX4
4.1/5
Sony CRE-C10
US$999
CIC
✗
✗
✗
IPX2
3.8/5
Jabra Enhance Plus
US$799
TWS
✓
✓
✓
IP52
3.9/5
Lexie by Bose
US$999
RIC
✓
✓
✓
IP52
4.0/5
HP Hearing PRO
US$699
RIC
✓
✓
✓
IP68
3.7/5
Amazon budget brands
US$50–200
BTE/ITE
Some
Some
✗
Varies
2.5–3.5
OTC's impact on prescription hearing aid pricing.Current evidence shows OTC exerts limited direct price pressure on the prescription market, for two reasons: (1) the target audiences differ—OTC reaches people with mild loss who wouldn't otherwise buy a hearing aid, not existing prescription customers; and (2) traditional hearing aid prices bundle in professional value such as fitting, real-ear measurement, and follow-up adjustment. OTC has, however, accelerated unbundling—more clinics now quote products and services separately so consumers can compare device-only prices.
Flagship prescription (pair)
6000
Mid-tier prescription (pair)
3500
Entry prescription (pair)
1500
Branded OTC (pair)
900
Amazon OTC (pair)
120
Average retail price of prescription vs. OTC hearing aids (USD/pair), 2024
Consumer Behavior & Satisfaction
MarkeTrak 2024 survey data reveals a pronounced satisfaction gap between OTC users and those fitted professionally. This goes beyond product quality—it reflects that hearing care is a service-intensive field where product delivery alone can't meet users' real needs.
OTC return rate
30%
Prescription return rate
5%
OTC vs. professionally fitted hearing aid return rates
Top OTC User Complaints
Fit discomfort (wrong dome size, pressure)
Sound-quality expectation gap (feedback, amplified noise)
Lack of follow-up adjustment and professional support
Inaccurate self-administered hearing assessment
Complexity of operating product features
Positive Signals
~15% of OTC users later upgrade to prescription hearing aids
OTC lowers the psychological barrier to a first fitting
Highest acceptance among younger users (ages 45–60)
Marked reduction in hearing-loss stigma
Tech enthusiasts driving positive word of mouth
Who is buying OTC?MarkeTrak data shows OTC buyers differ markedly in profile from traditional prescription users:
Attribute
OTC buyers
Prescription users
Average age
54
71
Household income
US$85,000+
US$55,000
Degree of hearing loss
Mostly mild (72%)
Mostly moderate (58%)
Tech literacy
High (heavy smartphone users)
Moderate
Primary motivation
Curiosity/trial, attractive price
Doctor or family recommendation
Channel Structure Impact
Perhaps the most far-reaching effect of OTC deregulation lies in its impact on hearing aid channel structure, rather than simply OTC market share. This shift is accelerating three trends: the expansion of big-box retail, the rise of online channels, and the unbundling of professional services.
Before OTC (2021)
Independent clinics 40%
Chain hearing centers 25%
Costco / big-box retail 20%
VA / government 12%
Online / other 3%
After OTC (2025E)
Independent clinics 30%
Chain hearing centers 22%
Costco / big-box retail 22%
VA / government 11%
OTC retail channels 8%
Online DTC 7%
Shift in U.S. hearing aid sales channel share (before vs. after OTC)
01
Independent clinics — mounting revenue pressure
Independent clinics face a double squeeze: OTC siphons off entry-level customers with mild loss while big-box retailers like Costco keep undercutting the moderate-loss segment on price. Surveys show roughly 35% of independent clinics saw revenue fall 10–15% after OTC opened.
Costco continues to dominate the value prescription market with its Kirkland-brand aids at US$1,499/pair. Best Buy has invested millions in in-store hearing sections, and Walmart and Sam's Club are expanding OTC shelf space. These channels hold a hybrid-model advantage: OTC display plus professional fitting.
03
Online channels — fast growth, real challenges
OTC hearing aid listings on Amazon grew from ~200 to ~1,500+ in two years, but a flood of low-quality products keeps the average rating at just 3.2/5. Manufacturer DTC sales (Sony, Jabra) grow steadily but remain limited in scale.
04
Unbundling — separating product from service
OTC's most fundamental industry effect is accelerating unbundling—consumers now question why a hearing aid's price includes years of bundled service. More clinics are introducing standalone service pricing, separating the device cost from adjustment, maintenance, and consultation fees.
Global Regulatory Spillover
The FDA's OTC rule is creating global ripple effects. Regulators worldwide—notably Australia's TGA, the EU's MDR framework, and China's NMPA—are studying whether to establish similar OTC categories. But with wide differences in health-system structure, audiologist workforce distribution, and insurance models, regulatory diffusion will move far slower than the market expects.
Country / Region
OTC status
Expected timing
Key developments
United States
Open
2022
FDA OTC category in effect; consumers can buy directly
European Union
Under review
2025–2027
OTC category feasibility under discussion within the MDR framework
Japan
De facto OTC
—
Sound amplifiers fall outside medical device rules, creating a de facto self-purchase market
Australia
Under review
2025+
The TGA is consulting publicly, referencing the FDA model
India
Low barrier
—
Loose enforcement of hearing aid rules leaves the market flooded with counterfeits
China
Tiered control
2024+
The NMPA is drafting an OTC category, referencing the FDA maximum-output standard
South Korea
Prescription only
2026+
The MFDS has not yet begun OTC rulemaking
Taiwan
Prescription only
—
The TFDA classifies hearing aids as Class II medical devices, requiring fitting by an audiologist
Industry Outlook
The global spread of OTC rules is creating unprecedented operational complexity for hearing-care retailers—multi-brand management, mixed OTC-plus-prescription inventory, unbundled pricing strategies, and surging consumer-education needs. AI operations systems will become the core tool for retailers to stay competitive in the complex post-OTC era.
Forward Analysis: OTC's Second Curve
The first OTC wave (2022–2025) was a test-the-waters phase—immature products, low consumer awareness, and inexperienced retail channels. The second wave (2025–2030) is expected to deliver genuine structural change:
01
Better products
Consumer-electronics giants like Apple and Samsung will release earbuds with integrated hearing assistance. AirPods Pro 2 has already earned FDA clearance, and AI-driven self-fitting algorithms will sharply improve the first-fit OTC experience.
02
Better self-fitting
Machine-learning models paired with a smartphone's built-in microphone and sensors can deliver a near-professional hearing assessment in 3–5 minutes. Apple's Hearing Test feature has already proven this path viable.
03
Better retail experience
Retail channels staffed by hearing professionals will become hybrid sales points for both OTC and prescription. Consumers can try OTC first, then upgrade to prescription as needed—a seamless customer journey.
10–15%
Projected 2030 global OTC market share
≠ 30–40%
Revised optimistic forecast
Conclusion: OTC expands the overall market rather than cannibalizing the professional one.The data shows OTC mainly reaches people who wouldn't otherwise have bought a hearing aid—younger, higher-income, mild loss, and tech-savvy. Moderate-to-severe loss, complex loss patterns, and older populations still rely heavily on professional fitting. OTC's real value is growing the overall pie while creating a new pipeline of upgrade customers for professional hearing care.
FDA Final Rule 21 CFR Part 800 (2022)
Hearing Industries Association Quarterly Reports (2023–2025)
MarkeTrak 2024 Consumer Survey
NASEM. Hearing Health Care for Adults (2016)
Consumer Reports OTC Hearing Aid Reviews (2024)
JAMA Otolaryngology OTC Outcomes Study (2024)
Amazon Hearing Aid Category Sales Data
INTELLIGENCE REPORT
Subscribe to the Intelligence Report
Get every new hearing-care industry report delivered straight to your inbox.